Why Doctors Prefer FDA-Approved Bioidentical Hormones

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: August 10, 2026

Key Takeaways on Hormones and Peptides

• Most physicians prescribe FDA-approved bioidentical hormones because compounded versions lack standardized manufacturing, batch testing, and adverse-event reporting.
• ACOG, the Endocrine Society, and NASEM advise against routine use of compounded bioidentical hormone therapy when FDA-approved options exist, citing dosing variability and limited safety data.
• Compounded preparations can vary in hormone content, which raises concerns about endometrial protection and overall safety.
• Salivary hormone testing is not reliable for dosing decisions. Serum testing remains the validated clinical standard.
• Patients who want evidence-based hormone or peptide therapy can work with Mirror Plastic Surgery to explore personalized, medically supervised care.

Why Most Physicians Choose FDA-Approved Bioidentical Hormones

ACOG Clinical Consensus No. 6 (2023) advises against routine use of compounded bioidentical menopausal hormone therapy when FDA-approved formulations are available. The guidance cites dosing variability and limited regulatory oversight. This view aligns with other major medical organizations.

The 2020 National Academies of Sciences, Engineering, and Medicine (NASEM) report found that compounded bioidentical hormone therapy products present safety concerns related to variable quality and potency and that no evidence shows they are safer or more effective than FDA-approved therapies. The 2022 NAMS Position Statement supports hormone therapy as an appropriate first-line option for symptomatic menopausal women under 60 or within 10 years of menopause onset.

FDA-approved HRT products complete premarket clinical trials that evaluate safety, efficacy, and manufacturing consistency, while compounded HRT does not. In addition, on February 12, 2026, the FDA updated labeling for six menopausal hormone therapy products and removed outdated boxed warnings about cardiovascular disease, breast cancer, and probable dementia. This regulatory change further supports the use of FDA-approved options when appropriate.

Risks Linked to Dose Variability in Compounded Hormones

Stanczyk et al. (Menopause 2019;26:966–71) analyzed compounded estradiol and progesterone capsules and creams from 13 compounding pharmacies. The study found that hormone content in some products differed from the labeled dose. Progesterone excess or deficiency can compromise endometrial protection and create safety concerns.

Compounded HRT preparations that meet Section 503A conditions are exempt from three key safeguards: cGMP manufacturing standards, standardized labeling requirements, and premarket approval. These exemptions mean that dose consistency is not enforced through the same manufacturing controls that apply to FDA-approved products. Compounding pharmacies under Section 503A also do not have to report adverse events to the FDA, which limits systematic safety surveillance and makes it harder to detect patterns of harm.

Pellet implants, a compounded format, can produce variable estradiol levels after insertion. Observational studies have reported higher rates of side effects with pellet therapy compared with FDA-approved hormone therapy. Pellets cannot be removed once implanted, so any dosing issue must run its course.

Why Saliva Testing Falls Short for Hormone Dosing

Clinicians generally do not rely on salivary sex-hormone testing to diagnose conditions or to start, stop, or adjust hormone therapy. Measurement reliability remains the central concern.

A 2026 review by Newman et al. in Frontiers in Reproductive Health outlines limitations of salivary testing for monitoring transdermal testosterone therapy.

Studies show variable correlations between salivary and serum concentrations of estradiol and progesterone. Serum testing continues to serve as the validated standard for dosing decisions.

FDA-Approved vs. Compounded Bioidentical Hormones: Practical Differences

The distinctions below reflect guidance from ACOG, the Endocrine Society and NAMS, and the 2020 NASEM report.

• Standardized manufacturing: FDA-approved products such as Estrace, Prometrium, and Estraderm follow cGMP manufacturing standards. Compounded preparations are exempt from cGMP under Section 503A.
• Batch testing: FDA-approved products undergo bioequivalence testing and pharmacokinetic characterization. Compounded products do not require independent batch verification.
• Dosing consistency: FDA-approved products provide predictable dose-to-dose absorption. Compounded products can deviate from the labeled dose.
• Adverse-event reporting: FDA-approved products feed into the MedWatch surveillance system. Compounded preparations do not have a centralized reporting requirement.
• Labeling: FDA-approved products include standardized warnings, contraindications, and risk information. Compounded hormone products are exempt from standardized FDA labeling.
• Clinical trial evidence: FDA-approved products are supported by premarket randomized controlled trials. Liu et al. (Menopause 2022) found that randomized controlled trial evidence for compounded bioidentical hormone therapy remains limited and does not confirm the safety and efficacy claims often made for these products.

Schedule a consultation to review evidence-based, medically supervised hormone therapy options that match your health profile.

Key Terms for Hormone and Peptide Therapy

• Bioidentical: Hormones that share the same molecular structure as hormones produced by the human body, such as 17β-estradiol and micronized progesterone. Both FDA-approved and compounded products can be bioidentical.
• Compounded: A preparation custom-mixed by a compounding pharmacy for an individual prescription. Compounded products are not FDA-approved and do not undergo premarket safety or efficacy review.
• FDA-approved: A drug that has completed premarket review for safety, efficacy, and manufacturing quality under 21 CFR regulations. These products include standardized labeling and post-market surveillance.
• Peptide: A short chain of amino acids that acts as a signaling molecule. Therapeutic peptides, when prescribed, target specific processes such as inflammation, tissue repair, metabolic function, and cellular energy under medical supervision.

Non-Hormonal, Evidence-Based Options for Menopause Symptoms

Some adults cannot use hormone therapy or prefer to avoid it. Several non-hormonal options have meaningful clinical support. Low-dose SSRIs and SNRIs can ease menopausal hot flashes in people who cannot take estrogen or who also need treatment for a mood disorder.¹ Fezolinetant (Veozah) and elinzanetant (Lynkuet) are FDA-approved, hormone-free medicines that act on brain pathways that regulate body temperature to treat hot flashes. Cognitive behavioral therapy can reduce how much menopause symptoms bother patients by helping shift unhelpful thoughts, feelings, and behaviors.¹

A 2026 narrative review in the Journal of Menopausal Medicine highlights physical activity with resistance training, Mediterranean-style diet quality, and weight management as strategies that support cardiometabolic, musculoskeletal, sleep, and mood health with low risk during the menopausal transition.

Some patients also look for a personalized, supervised approach to inflammation, weight management, and energy when standard options have not delivered enough relief. For these individuals, medically supervised peptide therapy can serve as an additional pathway under qualified clinical oversight.

Peptide therapy does not replace hormone therapy. It supports a different but complementary set of health goals. The next section explains how Mirror Plastic Surgery structures peptide protocols, who may be a good candidate, and what to expect from care.

How Medically Supervised Peptide Therapy Works at Mirror Plastic Surgery

Peptide therapy at Mirror Plastic Surgery starts with a 30–60 minute consultation with Ellie Pranckevicius, FNP-BC. This visit covers medical history, current medications, and specific health goals. For weight management or inflammatory concerns, Ellie reviews or orders comprehensive lab panels that assess thyroid, liver, kidney, diabetes markers, and hormone levels.

Ellie then designs a custom peptide protocol. Examples include the Glow Stack (GHK-CU, BPC-157, TB500) for systemic inflammation and collagen support, GLP-3R for weight management and metabolic health, NAD for cellular energy and healthy aging, and Selank for anxiety support without the dependency profile of benzodiazepines. Protocols are individualized and reflect each person’s physiology and goals.

Ongoing monitoring is built into care. Patients have 24/7 text access to Ellie for questions, refill requests, and protocol adjustments. The full process, from consultation through prescription and delivery, can occur in person at the St. Petersburg, Florida office or remotely across the United States, including Hawaii and Alaska.

Start with a comprehensive lab review and personalized peptide protocol design with Ellie Pranckevicius, FNP-BC.

Meet Your Peptide and Aesthetics Practitioner

Ellie Pranckevicius, FNP-BC, is a board-certified Family Nurse Practitioner who leads peptide therapies and non-surgical aesthetics at Mirror Plastic Surgery. She holds a Bachelor’s in Health Science from Boston University, completed an aesthetics licensure program, and earned both her Bachelor’s and Master’s in Nursing from the University of South Florida. She spent four years in the Neuroscience ICU at Tampa General Hospital, where she developed deep experience in physiology, metabolic health, and complex recovery.

Ellie focuses on education and transparency. She explains the physiology behind each recommendation in clear language so patients understand what they are taking and why. She also tells patients when a service or product is not yet necessary, prioritizing long-term outcomes over short-term revenue. Her combined background in esthetics and advanced clinical nursing allows her to connect aesthetic goals with the medical science required to pursue them safely.

Current Regulatory Landscape for Peptide Therapies

Most therapeutic peptides are not FDA-approved for the wellness indications discussed here. Clinicians worldwide still use them under supervision, supported by more than a decade of research on inflammation, metabolic health, tissue repair, and neurological function. Lack of FDA approval usually reflects an incomplete formal approval pathway rather than a total absence of safety data.

Sourcing quality creates the greatest risk in peptide use. Unregulated online retailers sell peptides without third-party quality verification, accurate dosing confirmation, or clinical oversight. Mirror Plastic Surgery sources peptides only from reputable providers that perform rigorous batch testing and supply certificates of analysis for purity and dosing consistency. This approach separates supervised medical use from the unverified online market.

The regulatory environment continues to evolve. The FDA’s Pharmacy Compounding Advisory Committee held a July 2026 vote on nominated peptides, signaling active agency review of which compounded peptides should remain available and under what conditions. Patients benefit from working with a clinician who tracks these developments and adjusts sourcing and protocols as regulations change.

Decision-Making Factors and Realistic Limits of Peptide Therapy

Peptide therapy does not fit every patient, and expectations need to stay realistic. Several factors should guide decisions about whether to start therapy and what results to expect.

• Sourcing quality: Batch-tested peptides from verified providers are essential for safety. Products from unregulated sources carry unknown purity and potency risks.
• Lab monitoring: Baseline and follow-up labs help confirm safety and guide dosing adjustments, especially for metabolic and weight-management protocols.
• Outcome variability: Results differ between individuals based on genetics, lifestyle, diet, and the specific protocol.¹ No outcome can be guaranteed.
• Maintenance requirements: Benefits usually depend on continued use. Stopping a protocol often leads to a gradual return toward baseline, similar to pausing other health regimens.
• Need for medical supervision: Without clinical oversight and verified sourcing, dosing accuracy and product integrity cannot be confirmed, and potential interactions or contraindications may go unnoticed.

Three Misconceptions About Hormones and Peptides

Misconception 1: All bioidentical hormones are identical regardless of source. The term “bioidentical” describes molecular structure, not manufacturing quality. Compounded bioidentical hormones can vary from batch to batch in dose and purity, while FDA-approved bioidentical hormones undergo standardized manufacturing and pharmacokinetic testing. The molecule may match, but the finished products differ in consistency and oversight.

Misconception 2: Saliva tests are sufficient for guiding hormone dosing. Saliva collection for estradiol testing can be distorted by topical hormone contamination, bleeding gums, recent food or drink, or toothbrushing, which can produce falsely elevated results. Serum testing remains the validated clinical standard for dosing decisions.

Misconception 3: Absence of FDA approval equals absence of safety data. Many peptides have been studied in clinical research for more than a decade in international settings. The key distinction lies between formal regulatory approval, which requires a completed premarket application, and the existence of safety and efficacy data, which can accumulate through peer-reviewed research and clinical experience even without a formal approval submission.

Get straightforward answers about peptide therapy and learn whether supervised treatment aligns with your specific health goals.

Frequently Asked Questions

Why do most doctors avoid prescribing compounded bioidentical hormones?

Most physicians follow the guidance from ACOG, the Endocrine Society, and NASEM discussed earlier in this article. Beyond regulatory and manufacturing concerns, many clinicians describe a practical pattern in their own practices. Patients on compounded hormones often present with symptoms of under- or over-dosing that improve after switching to FDA-approved formulations with consistent pharmacokinetics. The lack of standardized dosing in compounded products makes troubleshooting symptoms and adjusting therapy more difficult.

Are peptide therapies a replacement for hormone therapy?

Peptide therapies and hormone therapies serve different roles and are not interchangeable. Hormone therapy directly replaces or supplements declining hormones to manage symptoms such as hot flashes, vaginal atrophy, and bone loss. Peptide therapies act as signaling molecules that influence processes such as inflammation, tissue repair, metabolic function, and cellular energy without directly replacing hormones. Some patients use both approaches under medical supervision, while others pursue peptides alone when hormone therapy is unsuitable or not desired. A thorough clinical evaluation helps determine the right approach for each person.

How long does it take to see results from peptide therapy?

Timelines vary by peptide, target condition, and individual physiology. Some patients notice early changes in energy or inflammation within the first week.¹ Protocols aimed at collagen production, body composition, or metabolic markers usually require several weeks to months of consistent use before meaningful changes appear.¹ During the initial consultation, Ellie Pranckevicius outlines realistic timelines and uses follow-up lab panels to track objective progress alongside symptom changes.

What happens if I stop taking peptides?

Benefits from peptide therapy usually fade after a protocol stops.¹ Inflammation that was being modulated often returns toward its prior level.¹ Metabolic improvements may lessen, and energy gains tied to mitochondrial support can decline.¹ This pattern mirrors most health interventions, where stopping a regimen removes its ongoing effect. Maintenance protocols can help sustain results, and Ellie works with each patient to design a long-term plan that fits their lifestyle and goals.

Is it safe to buy peptides online without medical supervision?

Buying peptides from unregulated online sources carries significant risk. Without third-party batch testing, there is no way to confirm product identity, purity, or dose accuracy. Skipping a clinical evaluation also removes screening for contraindications, drug interactions, and underlying conditions that could affect safety. At Mirror Plastic Surgery, peptides come only from providers with documented batch testing, and every protocol follows a detailed medical history review and, when indicated, lab panels. Medical supervision functions as the safety framework that separates responsible peptide use from self-directed experimentation.

---